专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013021027A2 MATRIX AND METHOD FOR PURIFYING AND/OR ISOLATING NUCLEIC ACIDS 审中-公开
标题翻译：用于纯化和/或分离核酸的基质和方法
公开(公告)号：WO2013021027A2
公开(公告)日：2013-02-14
申请号：PCT/EP2012/065574
申请日：2012-08-09
申请人： WIRTZ, Ralph, Markus
发明人： WIRTZ, Ralph, Markus
CPC分类号： C12N15/101 , C12N15/1006 , C12Q2563/137 , C12Q2563/143 , C12Q2563/155
摘要： The present invention relates to matrix materials suitable for use in purifying and/or isolating nucleic acids from a biological sample, which matrix comprises a surface comprising at least one element selected from the group consisting of Germanium, Tin and/or Lead, or at least one salt thereof, and methods related therewith.
摘要翻译：本发明涉及适用于从生物样品中纯化和/或分离核酸的基质材料，该基质包含含有至少一种选自下列的元素的表面：锗，锡和/或铅或其至少一种盐，以及与其相关的方法。

2. 发明申请

WO2009068445A1 THE PRESENT INVENTION RELATES TO METHODS FOR PREDICTION OF THE THERAPEUTIC SUCCESS OF BREAST CANCER THERAPY 审中-公开
标题翻译：本发明涉及用于预测乳腺癌治疗效果的方法
公开(公告)号：WO2009068445A1
公开(公告)日：2009-06-04
申请号：PCT/EP2008/065517
申请日：2008-11-14
申请人： SIEMENS HEALTHCARE DIAGNOSTICS GMBH , WIRTZ, Ralph Markus , MILDE-LANGOSCH, Karin , IHNEN, Maike , SCHRÖDER, Christine
发明人： WIRTZ, Ralph Markus , MILDE-LANGOSCH, Karin , IHNEN, Maike , SCHRÖDER, Christine
IPC分类号： C07K16/00 , C12Q1/68 , G01N33/574
CPC分类号： G01N33/57442 , C12Q1/6886 , C12Q2600/106 , G01N33/57411 , G01N33/57415 , G01N33/57449 , G01N2333/485 , G01N2333/51 , G01N2333/70546 , G01N2333/96411 , G01N2800/52
摘要： The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing gynecologic cancer towards a given mode of treatment, said method comprising the steps of : a) obtaining a biological sample from said patient; b) determining the expression level of at least one gene selected from the group comprising ALCAM, Osteopontin, Her-2/neu, EGFR, uPA/PAI-1 and/or ESRl, in particular of ALCAM and/or Osteopontin, in said sample; c) comparing the pattern of expression level (s) determined in (b) with one or several reference pattern (s) of ex pression levels; and d) predicting therapeutic success for said given mode of treatment in said patient or implementing therapeutic regimen in said patient from the outcome of the comparison in step (c).
摘要翻译：本发明涉及一种用于预测患有或处于发展妇科癌症风险的患者的临床反应朝向给定治疗方式的方法，所述方法包括以下步骤：a）从所述患者获得生物样品; b）确定所述样品中至少一种选自ALCAM，骨桥蛋白，Her-2 / neu，EGFR，uPA / PAI-1和/或ESR1，特别是ALCAM和/或骨桥蛋白的基因的表达水平 ; c）将（b）中确定的表达水平的模式与一个或几个表观水平的参考模式进行比较; 以及d）根据步骤（c）中的比较结果预测所述患者中所述给定治疗方式的治疗成功或实施所述患者的治疗方案。

3. 发明申请

WO2009068409A1 A METHOD TO ASSESS PROGNOSIS AND TO PREDICT THERAPEUTIC RESPONSE TO ENDOCRINE TREATMENT 审中-公开
标题翻译：评估预防和预防治疗内皮抑素治疗的方法
公开(公告)号：WO2009068409A1
公开(公告)日：2009-06-04
申请号：PCT/EP2008/064763
申请日：2008-10-31
申请人： SIEMENS HEALTHCARE DIAGNOSTICS GMBH , WIRTZ, Ralph , HENNIG, Guido , VON TÖRNE, Christian
发明人： WIRTZ, Ralph , HENNIG, Guido , VON TÖRNE, Christian
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/16
摘要： The present invention is related to a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease to a given mode of treatment by determination the status of at least one hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor, said method comprising the steps of : a) obtaining a biological sample from said patient; b) determining the status of at least one hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor in said sample, using at least two determinations selected from the group comprising: aa) determining the expression level of the RNA transcripts of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor, and/or bb) determining the DNA amplification level of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor, and/or cc) determining the presence or absence of at least one single nucleotide polymorphism of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor; c) comparing the pattern of expression level (s) of aa), amplification level (s) of bb) and/or the single nucleotide polymorphism (s) of cc) determined in step b) with one or several reference pattern (s) of expression and/or amplification levels and/or single nucleotide polymorphisms; and d) predicting therapeutic outcome for said given mode of treatment in said patient from the outcome of the comparison in step c).
摘要翻译：本发明涉及通过测定至少一种激素受体的状态来预测患有或具有发展为肿瘤疾病的风险的患者的给定治疗方式的临床反应的方法，该至少一种激素受体选自雌激素受体，孕酮受体和/或雄激素受体，所述方法包括以下步骤：a）从所述患者获得生物样品; b）使用选自以下的至少两种测定来确定所述样品中选自雌激素受体，孕酮受体和/或雄激素受体的至少一种激素受体的状态：aa）确定所述RNA的表达水平编码选自雌激素受体，孕酮受体和/或雄激素受体的激素受体的至少一个基因的转录物和/或bb）测定编码激素受体的至少一个基因的DNA扩增水平，所述激素受体选自包括雌激素受体，孕酮受体和/或雄激素受体的组，和/或cc）确定至少一种编码激素受体的基因的至少一个单核苷酸多态性的存在或不存在，所述激素受体选自雌激素受体，孕酮受体和/或雄激素受体; c）将步骤b）中确定的aa的表达水平，bb的扩增水平和/或cc的单核苷酸多态性与一种或多种参考模式进行比较，的表达和/或扩增水平和/或单核苷酸多态性; 以及d）从步骤c）中比较的结果预测所述患者中所述给定治疗模式的治疗结果。

4. 发明申请

WO2009047062A2 MOLECULAR MARKERS FOR CANCER PROGNOSIS 审中-公开
标题翻译：癌症预防分子标记
公开(公告)号：WO2009047062A2
公开(公告)日：2009-04-16
申请号：PCT/EP2008/061752
申请日：2008-09-05
申请人： SIEMENS HEALTHCARE DIAGNOSTICS GMBH , STROPP, Udo , VON TÖRNE, Christian , WIRTZ, Ralph
发明人： STROPP, Udo , VON TÖRNE, Christian , WIRTZ, Ralph
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G01N33/574 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57415 , G01N2800/54 , G01N2800/56
摘要： The invention is predicated on the finding that the gene expression level of two genes, GAPDH and RPL37A, already exhibits a powerful predictive power for assessing the outcome of a neoplastic or cancerous disease. The invention relates to a method for predicting an outcome of a patient suffering from or at risk of developing a neoplastic disease, said method comprising the steps of: a) obtaining a biological sample from said patient; b) quantif iably determining the gene expression level of GAPDH or RPL37A and at least one further housekeeping gene, wherein the expression level of GAPDH or RPL37A is determined in relation to the expression level of the at least one further housekeeping gene; c) arriving at a prediction by means of a mathematical discriminate function.
摘要翻译：本发明基于两个基因GAPDH和RPL37A的基因表达水平已经表现出用于评估肿瘤或癌性疾病的结果的强大预测能力的发现。本发明涉及一种用于预测患有或有发展为肿瘤疾病风险的患者的结果的方法，所述方法包括以下步骤：a）从所述患者获得生物样品; b）定量地确定GAPDH或RPL37A和至少一个另外的管家基因的基因表达水平，其中GAPDH或RPL37A的表达水平与至少一个另外的管家基因的表达水平相关; c）通过数学鉴别函数到达预测。

5. 发明申请

WO2009030605A2 A METHOD FOR PREDICTING A CLINICAL RESPONSE OF A PATIENT SUFFERING FROM OR AT RISK OF DEVELOPING A NEOPLASTIC DISEASE TOWARDS A GIVEN MODE OF TREATMENT 审中-公开
标题翻译：一种预测患有或可能发展为肿瘤性疾病的患者的临床反应的方法，其具有治疗模式
公开(公告)号：WO2009030605A2
公开(公告)日：2009-03-12
申请号：PCT/EP2008/061113
申请日：2008-08-26
申请人： SIEMENS HEALTHCARE DIAGNOSTICS GMBH , WIRTZ, Ralph , BRÜCKL, Wolfgang
发明人： WIRTZ, Ralph , BRÜCKL, Wolfgang
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158
摘要： The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards a given mode of treatment, said method comprising the steps of : a) obtaining a biological sample from said patient; b) determining the expression level of at least one ligand from the Vascular endothelial growth factor (VEGF) family and/or of at least one receptor from the Vascular endothelial growth factor receptor (VEGFR) family in said patient, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern (s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said subject or implementing therapeutic regimen targeting the signalling pathway said ligand is related to in said subject from the outcome of the comparison in step (c).
摘要翻译：本发明涉及用于预测患有或处于发展成肿瘤性疾病的风险的患者对于给定治疗模式的临床反应的方法，所述方法包括以下步骤：a）获得来自所述患者的生物样品; b）确定所述患者中来自血管内皮生长因子（VEGF）家族和/或来自血管内皮生长因子受体（VEGFR）家族的至少一种受体的至少一种配体的表达水平，c）比较（b）中用一种或多种参考模式表达水平确定的表达水平; 和d）预测所述受试者的所述给定治疗模式的治疗成功或实施治疗方案，所述治疗方案靶向所述配体与步骤（c）中的比较结果在所述受试者中相关的信号传导途径。

6. 发明申请

WO2007015935A3 DIAGNOSTIC METHODS FOR THE PREDICTION OF THERAPEUTIC SUCCESS, RECURRENCE FREE AND OVERALL SURVIVAL IN CANCER THERAPY 审中-公开
公开(公告)号：WO2007015935A3
公开(公告)日：2007-08-23
申请号：PCT/US2006028180
申请日：2006-07-20
申请人： BAYER HEALTHCARE LLC , WIRTZ RALPH MARKUS
发明人： WIRTZ RALPH MARKUS
IPC分类号： C12Q1/68 , A61K39/395 , C12N15/113
CPC分类号： C12Q1/6886 , C12N15/1136 , C12Q2600/106 , C12Q2600/118 , C12Q2600/136
摘要： Described are 12 human genes which are differentially expressed in neoplastic tissues of patients responding well to treatment as compared to patients not responding well as determined by overall survival time in the non responding cohort. Moreover, methods for prognosis of the therapeutic success in cancer therapy are described. These methods are based on determination of expression levels of particular genes which are differentially expressed in cancer patients, preferably the genes encoding VEGFC, ERBB3 and Her2/neu, prior to the onset of anti-cancer chemotherapy. These methods are particularly useful in the investigation of advanced head and neck cancer, but are useful in the investigation of other types of cancer and therapies as well.

7. 发明申请

WO2006015742A2 TUMOR MARKER FOR USE IN THE DIAGNOSIS OF CARCINOMAS AND/OR METASTASES ORIGINATING THEREFROM 审中-公开
标题翻译：肿瘤标记物的诊断癌症和/或由其衍生的转移灶
公开(公告)号：WO2006015742A2
公开(公告)日：2006-02-16
申请号：PCT/EP2005008274
申请日：2005-07-29
申请人： UNIV FRIEDRICH ALEXANDER ER , BRUECKL WOLFGANG MICHAEL , WEIN AXEL , MUNNES MARC , WIRTZ RALPH MARKUS
发明人： BRUECKL WOLFGANG MICHAEL , WEIN AXEL , MUNNES MARC , WIRTZ RALPH MARKUS
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
摘要： The invention relates to a method (i) for detecting a carcinoma, especially an adenocarcinoma, preferably a gastrointestinal carcinoma and more preferably a colorectal carcinoma, (ii) for predicting metastases, preferably liver metastases, depending on a primary colon carcinoma and/or (iii) for predicting the response of metastases to a 5-fluorouracil-containing chemotherapy. The inventive method comprises determining a gene expression profile of 120 marker genes or a selection thereof.
摘要翻译：本发明特别涉及的腺癌，优选胃肠癌，特别优选为大肠癌，用于检测癌的方法（i），（ii）用于转移的预测，优选的肝转移（依赖于原发性结肠癌和/或iii ）用于预测转移到基于5-氟尿嘧啶的化疗包括确定120个标记基因的基因表达图谱或它们的选择的响应。

8. 发明申请

WO2005047534A2 METHODS AND COMPOSITIONS FOR THE RESPONSE PREDICTION OF MALIG-NANT NEOPLASIA TO TREATMENT 审中-公开
标题翻译：用于治疗MALIG-NANT NEOPLASIA的反应预测的方法和组合物
公开(公告)号：WO2005047534A2
公开(公告)日：2005-05-26
申请号：PCT/EP2004011599
申请日：2004-10-15
申请人： BAYER HEALTHCARE AG , WIRTZ RALPH , MUNNES MARC
发明人： WIRTZ RALPH , MUNNES MARC
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/136
摘要： The invention provides novel compositions, methods and uses, for the prediction., diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer in particular. Genes that are differentially expressed in breast tissue of breast cancer patients versus those of normal people are disclosed.
摘要翻译：本发明提供了用于尤其是恶性肿瘤和乳腺癌的预测，诊断，预后，预防和治疗的新型组合物，方法和用途。披露了在乳腺癌患者乳房组织中与正常人乳腺组织差异表达的基因。

9. 发明申请

WO2011121028A1 ALGORITHM FOR PREDICTION OF BENEFIT FROM ADDITION OF TAXANE TO STANDARD CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER 审中-公开
标题翻译：将TAXANE增加益处的优点与乳腺癌患者标准化疗相关的算法
公开(公告)号：WO2011121028A1
公开(公告)日：2011-10-06
申请号：PCT/EP2011/054915
申请日：2011-03-30
申请人： SIEMENS HEALTHCARE DIAGNOSTICS INC. , FOUNTZILAS, George , GEHRMANN, Mathias , KRONENWETT, Ralf , STROPP, Udo , WEBER, Karsten , WIRTZ, Ralph
发明人： FOUNTZILAS, George , GEHRMANN, Mathias , KRONENWETT, Ralf , STROPP, Udo , WEBER, Karsten , WIRTZ, Ralph
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , G06F19/20 , G06F19/24
摘要： The invention relates to a method or predicting an outcome of cancer in a patient suffering from cancer, said method comprising : (a) determining in a biological sample from said patient the expression level of at least one marker gene selected from AKR1C3, MAP4, SPP1, CXCL9, PTGER3, and VEGFC; (b) comparing said expression level to a reference pattern of expression, wherein an increased expression of said at least one marker gene is indicative of said patient having a benefit from microtubule stabilizing agent-based cytotoxic chemotherapy.
摘要翻译：本发明涉及一种方法或预测患有癌症的患者的癌症结果，所述方法包括：（a）在来自所述患者的生物样品中测定至少一种选自AKR1C3，MAP4，SPP1的标志物基因的表达水平，CXCL9，PTGER3和VEGFC; （b）将所述表达水平与表达的参考模式进行比较，其中所述至少一种标记基因的增加的表达指示所述患者具有基于微管稳定剂的细胞毒性化学疗法的益处。

10. 发明申请

WO2010125117A3 A METHOD TO ASSESS PROGNOSIS AND TO PREDICT THERAPEUTIC SUCCESS IN CANCER BY DETERMINING HORMONE RECEPTOR EXPRESSION LEVELS 审中-公开
标题翻译：通过测定激素受体表达水平来评估癌症预防和预防癌症治疗成功的方法
公开(公告)号：WO2010125117A3
公开(公告)日：2011-04-21
申请号：PCT/EP2010055745
申请日：2010-04-28
申请人： WIRTZ RALPH
发明人： WIRTZ RALPH
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q1/6809 , C12Q2600/112 , C12Q2600/118 , C12Q2545/101
摘要： The present invention is related to a method of classifying a sample of a patient who suffers from or being at risk of developing cancer, said method comprising the steps of determining in said sample from said patient, on a non-protein basis, the expression level of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor in said sample; comparing the one or more expression level(s) determined with one or more expression level(s) of one or more reference genes, and classifying the sample of said patient from the outcome of the comparison into one of at least two classifications.
摘要翻译：本发明涉及对患有癌症或患有癌症风险的患者的样品进行分类的方法，所述方法包括以非蛋白质的方式在所述患者的所述样品中以非蛋白质的形式确定所述样品的表达水平至少一种编码激素受体的基因，所述激素受体选自所述样品中的雌激素受体，孕酮受体和/或雄激素受体; 将由一个或多个参考基因的一个或多个表达水平确定的一个或多个表达水平进行比较，并将所述患者的样品从比较结果分类为至少两个分类中的一个。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式